Method of detecting and/or identifying adeno-associated virus (AAV) sequences and isolating novel sequences identified thereby

US11041171B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-11041171-B2
Application numberUS-202016682712-A
CountryUS
Kind codeB2
Filing dateNov 13, 2019
Priority dateNov 13, 2001
Publication dateJun 22, 2021
Grant dateJun 22, 2021

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Adeno-associated virus rh.20 sequences, vectors containing same, and methods of use are provided.

First claim

Opening claim text (preview).

The invention claimed is: 1. A method of generating a recombinant adeno-associated virus (AAV) comprising culturing a host cell containing: (a) a molecule encoding the AAV vp1 capsid protein having a sequence of amino acids 1 to 738 of SEQ ID NO: 85, or a sequence which is at least 95% identical to the full length of amino acids 1 to 738 of SEQ ID NO: 85; (b) a functional rep gene; (c) a nucleic acid molecule comprising at least one AAV inverted terminal repeat (ITR) and a non-AAV nucleic acid sequence encoding a gene product operably linked to sequences which direct expression of the product in a host cell; and (d) sufficient helper functions to permit packaging of the minigene into the AAV capsid protein under conditions which permit packaging of the minigene into the AAV capsid. 2. The method of claim 1 , wherein the sequence of the vp1 protein is at least 97% identical to the full length of amino acids 1 to 738 of SEQ ID NO: 85. 3. The method of claim 1 , wherein the sequence of the vp1 protein is at least 99% identical to the full-length of amino acids 1 to 738 of SEQ ID NO: 85. 4. The method of claim 1 , wherein the sequence of the vp1 protein is the full-length of amino acids 1 to 738 of SEQ ID NO: 85. 5. The method of claim 1 , wherein the gene product is alpha-1 antitrypsin, Factor VIII, Factor IX, ornithine transcarbamylase, glucose-6-phosphatase, phenylalanine hydroxylase, argininosuccinate synthetase, β-glucuronidase (GUSB), or a dystrophin protein. 6. The method of claim 1 , wherein the molecule is a nucleic acid molecule comprising nucleotides 844 to 3057 of SEQ ID NO: 27, or a nucleotide sequence at least 99% identical to nucleotides 844 to 3057 of SEQ ID NO: 27. 7. The method of claim 1 , wherein the rep gene is from AAV2. 8. A method of generating a recombinant adeno-associated virus (AAV) comprising culturing a host cell containing: (a) a molecule encoding the AAV vp2 capsid protein having a sequence of amino acids 138 to 738 of SEQ ID NO: 85, or a sequence which is at least 95% identical to the full length of amino acids 138 to 738 of SEQ ID NO: 85; (b) a functional rep gene; (c) a nucleic acid molecule comprising at least one AAV inverted terminal repeat (ITR) and a non-AAV nucleic acid sequence encoding a gene product operably linked to sequences which direct expression of the product in a host cell; and (d) sufficient helper functions to permit packaging of the minigene into the AAV capsid protein under conditions which permit packaging of the minigene into the AAV capsid. 9. The method of claim 8 , wherein the sequence of the vp2 protein is at least 97% identical to the full length of amino acids 138 to 738 of SEQ ID NO: 85. 10. The method of claim 8 , wherein the sequence of the vp2 protein is at least 99% identical to the full-length of amino acids 138 to 738 of SEQ ID NO: 85. 11. The method of claim 8 , wherein the sequence of the vp2 protein is the full-length of amino acids 138 to 738 of SEQ ID NO: 85. 12. The method of claim 8 , wherein the gene product is alpha-1 antitrypsin, Factor VIII, Factor IX, ornithine transcarbamylase, glucose-6-phosphatase, phenylalanine hydroxylase, argininosuccinate synthetase, β-glucuronidase (GUSB), or a dystrophin protein. 13. The method of claim 8 , wherein the molecule is a nucleic acid molecule comprising nucleotides 1255 to 3057 of SEQ ID NO: 27, or a nucleotide sequence at least 99% identical to nucleotides 1255 to 3057 of SEQ ID NO: 27. 14. The method of claim 8 , wherein the rep gene is from AAV2. 15. A method of generating a recombinant adeno-associated virus (AAV) comprising culturing a host cell containing: (a) a molecule encoding the AAV vp3 capsid protein having a sequence of amino acids 204 to 738 of SEQ ID NO: 85, or a sequence which is at least 95% identical to the full length of amino acids 204 to 738 of SEQ ID NO: 85; (b) a functional rep gene; (c) a nucleic acid molecule comprising at least one AAV inverted terminal repeat (ITR) and a non-AAV nucleic acid sequence encoding a gene product operably linked to sequences which direct expression of the product in a host cell; and (d) sufficient helper functions to permit packaging of the minigene into the AAV capsid protein under conditions which permit packaging of the minigene into the AAV capsid. 16. The method of claim 15 , wherein the sequence of the vp3 protein is at least 97% identical to the full length of amino acids 204 to 738 of SEQ ID NO: 85. 17. The method of claim 15 , wherein the sequence of the vp3 protein is at least 99% identical to the full-length of amino acids 204 to 738 of SEQ ID NO: 85. 18. The method of claim 15 , wherein the sequence of the vp3 protein is the full-length of amino acids 204 to 738 of SEQ ID NO: 85. 19. The method of claim 15 , wherein the gene product is alpha-1 antitrypsin, Factor VIII, Factor IX, ornithine transcarbamylase, glucose-6-phosphatase, phenylalanine hydroxylase, argininosuccinate synthetase, β-glucuronidase (GUSB), or a dystrophin protein. 20. The method of claim 15 , wherein the molecule is a nucleic acid molecule comprising nucleotides 1453 to 3057 of SEQ ID NO: 27, or a nucleotide sequence at least 99% identical to nucleotides 1453 to 3057 of SEQ ID NO: 27. 21. The method of claim 15 , wherein the rep gene is from AAV2.

Assignees

Inventors

Classifications

  • Receptors; Cell surface antigens; Cell surface determinants · CPC title

  • mammalian · CPC title

  • regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE · CPC title

  • Drugs for disorders of the respiratory system · CPC title

  • Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38) · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US11041171B2 cover?
Adeno-associated virus rh.20 sequences, vectors containing same, and methods of use are provided.
Who is the assignee on this patent?
Univ Pennsylvania
What technology area does this patent fall under?
Primary CPC classification C07K14/015. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Jun 22 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).